BMJ  2005;331:734 (1 October), doi:10.1136/bmj.331.7519.734

Paper

Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study

¹ Malaria Public Health and Epidemiology Group, Centre for Geographic Medicine, KEMRI/Wellcome Trust Collaborative Programme, PO box 43640, 00100 GPO, Nairobi, Kenya, ² Chainama Hills College Hospital of Health Sciences, Lusaka, Zambia, ³ Malaria Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA, ⁴ Center for International Health and Development, Boston University School of Public Health, Boston, MA 02118, USA, ⁵ Malaria Public Health and Epidemiology Group, Centre for Geographic Medicine, KEMRI/Wellcome Trust Collaborative Programme

Objective To evaluate treatment practices for uncomplicated malaria after the policy change from chloroquine to sulfadoxine-pyrimethamine and to artemether-lumefantrine in Zambia.

Design Cross sectional survey.

Setting Outpatient departments of all government and mission facilities in four districts in Zambia.

Participants 944 children with uncomplicated malaria seen by 103 health workers at 94 health facilities.

Main outcome measures Antimalarial prescriptions in accordance with national guidelines and influence of factors on health workers' decision to prescribeartemether-lumefantrine.

Results Artemether-lumefantrine, sulfadoxine-pyrimethamine, and chloroquine were available, respectively, at 48 (51%), 94 (100%), and 71 (76%) of the 94 facilities. Of 944 children with uncomplicated malaria, only one child (0.1%) received chloroquine. Among children weighing less than 10 kg, sulfadoxine-pyrimethamine was commonly prescribed in accordance with guidelines (439/550, 79.8%). Among the children weighing 10 kg or more, sulfadoxine-pyrimethamine was commonly prescribed (266/394, 68%), whereas recommended artemether-lumefantrine was prescribed for only 42/394 (11%) children. Among children weighing 10 kg or more seen at facilities where artemether-lumefantrine was available, the same pattern was observed: artemether-lumefantrine was prescribed for only 42/192 (22%) children and sulfadoxine-pyrimethamine remained the drug of choice (103/192, 54%). Programmatic activities such as in-service training and provision of job aids did not seem to influence the prescribing of artemether with lumefantrine.

Conclusion Although the use of chloroquine for uncomplicated malaria was succesfully discontinued in Zambia, the change of drug policy towards artemether-lumefantrine does not necessarily translate into adequate use of this drug at the point of care.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

What works for malaria
BMJ 2005 331: 0. [Full Text]

Antimalarial treatment with artemisinin combination therapy in Africa

Grace Malenga, Ayo Palmer, Sarah Staedke, Walter Kazadi, Theonest Mutabingwa, Evelyn Ansah, Karen I Barnes, and Christopher JM Whitty
BMJ 2005 331: 706-707. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• GUTHMANN, J.-P., COHUET, S., RIGUTTO, C., FORTES, F., SARAIVA, N., KIGULI, J., KYOMUHENDO, J., FRANCIS, M., NOEL, F., MULEMBA, M., BALKAN, S. (2006). High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in caala, central angola.. Am J Trop Med Hyg 75: 143-145 [Abstract] [Full text]  
• Volmink, J., Dare, L. (2005). Addressing inequalities in research capacity in Africa. BMJ 331: 705-706 [Full text]  
• Malenga, G., Palmer, A., Staedke, S., Kazadi, W., Mutabingwa, T., Ansah, E., Barnes, K. I, Whitty, C. J. (2005). Antimalarial treatment with artemisinin combination therapy in Africa. BMJ 331: 706-707 [Full text]  

Rapid Responses:

Read all Rapid Responses

Artemisinins for paediatric malaria: what still needs to be explored?

Renato Bertini Malgarini M.D., et al.
bmj.com, 7 Oct 2005 [Full text]